Literature DB >> 29264744

Deficiency of IL-18 Aggravates Esophageal Carcinoma Through Inhibiting IFN-γ Production by CD8+T Cells and NK Cells.

Jiantao Li1,2, Gang Qiu2, Baoshuan Fang2, Xiaohui Dai1, Jianhui Cai3.   

Abstract

To investigate the potential role of interleukin-18 (IL-18) in immunomodulation during tumorigenesis of esophageal carcinoma and elucidate the underlying molecular mechanism, we employed IL-18 knockout mice for this purpose. Carcinogen 4-nitroquinoline 1-oxide (4NQO) was administrated in drinking water to induce occurrence of esophageal squamous cell carcinoma (ESCC). T cell activation as indicated by the surface CD molecules was analyzed with flow cytometry. The serous content of interferon-γ (IFN-γ) along with other cytokines was determined by inflammatory human cytokine cytometric bead array. The cytotoxicity assay was performed by co-culture of tumor cells with immune cells and relative cell viability was determined by lactate dehydrogenase (LDH) assay. Apoptotic cells were stained with Annexin-V/propidium iodide (PI) and analyzed by flow cytometry. Cell proliferation was measured with Cell Counting Kit-8 (CCK-8) assay. Our data demonstrated that deficiency of IL-18 promoted the progression and development of 4NQO-induced ESCC. Loss of IL-18 suppressed the activation of T cells in the esophagus. Deficiency of IL-18 inhibited the IFN-γ production by CD8+ T cells and natural killer (NK) cells. Absence of IL-18 inhibited the cytotoxicity of CD8+ T cells and NK cell in vitro. Moreover, deficiency of IL-18 promoted the apoptosis of CD8+ T cells and inhibited the proliferation of CD8+ T cells in vitro. Our data elucidated the immunomodulatory role of IL-18 during tumorigenesis of ESCC, whose deficiency compromised antitumor immunity and contributed to immune escape of esophageal carcinoma. Our results also indicated the therapeutic potential of exogenous IL-18 against ESCC, which warrants further investigations.

Entities:  

Keywords:  Apoptosis; CD8+ T cell; Esophageal carcinoma; IFN-γ; IL-18

Mesh:

Substances:

Year:  2018        PMID: 29264744     DOI: 10.1007/s10753-017-0721-3

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  34 in total

1.  Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.

Authors:  Magali Terme; Evelyn Ullrich; Laetitia Aymeric; Kathrin Meinhardt; Jérôme D Coudert; Mélanie Desbois; François Ghiringhelli; Sophie Viaud; Bernard Ryffel; Hideo Yagita; Lieping Chen; Salaheddine Mécheri; Gilles Kaplanski; Armelle Prévost-Blondel; Masashi Kato; Joachim L Schultze; Eric Tartour; Guido Kroemer; Mariapia Degli-Esposti; Nathalie Chaput; Laurence Zitvogel
Journal:  Cancer Res       Date:  2012-03-16       Impact factor: 12.701

2.  Genetic variability at promoters of IL-18 (pro-) and IL-10 (anti-) inflammatory gene affects susceptibility and their circulating serum levels: An explorative study of prostate cancer patients in North Indian populations.

Authors:  Shailendra Dwivedi; Apul Goel; Sanjay Khattri; Anil Mandhani; Praveen Sharma; Sanjeev Misra; Kamlesh Kumar Pant
Journal:  Cytokine       Date:  2015-04-16       Impact factor: 3.861

3.  Geraniol modulates tongue and hepatic phase I and phase II conjugation activities and may contribute directly to the chemopreventive activity against experimental oral carcinogenesis.

Authors:  Arumugam Madankumar; Subramaniyan Jayakumar; Krishnan Gokuladhas; Balan Rajan; Subramanian Raghunandhakumar; Selvamani Asokkumar; Thiruvengadam Devaki
Journal:  Eur J Pharmacol       Date:  2013-03-13       Impact factor: 4.432

4.  Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication.

Authors:  Sofie Denies; Laetitia Cicchelero; Isabel Van Audenhove; Niek N Sanders
Journal:  J Control Release       Date:  2014-06-02       Impact factor: 9.776

5.  Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.

Authors:  Teruo Kaiga; Marimo Sato; Hide Kaneda; Yoichiro Iwakura; Tadatoshi Takayama; Hideaki Tahara
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

Review 6.  Inflammation and cancer: advances and new agents.

Authors:  Shanthini M Crusz; Frances R Balkwill
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

Review 7.  Epidemiologic differences in esophageal cancer between Asian and Western populations.

Authors:  Han-Ze Zhang; Guang-Fu Jin; Hong-Bing Shen
Journal:  Chin J Cancer       Date:  2012-04-13

8.  Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma.

Authors:  Chunhua Yang; Hang Cao; Ning Liu; Kai Xu; Meng Ding; Li-Jun Mao
Journal:  Drug Des Devel Ther       Date:  2016-11-15       Impact factor: 4.162

9.  Downregulation of HuR Inhibits the Progression of Esophageal Cancer through Interleukin-18.

Authors:  Xiaohui Xu; Cheng Song; Zhihua Chen; Chenxiao Yu; Yi Wang; Yiting Tang; Judong Luo
Journal:  Cancer Res Treat       Date:  2017-02-24       Impact factor: 4.679

10.  Substance use (alcohol, areca nut and cigarette) is associated with poor prognosis of esophageal squamous cell carcinoma.

Authors:  I-Chen Wu; Chun-Chieh Wu; Chien-Yu Lu; Wen-Hung Hsu; Meng-Chieh Wu; Jui-Ying Lee; Shah-Hwa Chou; Jang-Ming Lee; Yi-Ping Chou; Deng-Chyang Wu; Ming-Tsang Wu
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

View more
  13 in total

1.  Taurine Alleviates Schistosoma-Induced Liver Injury by Inhibiting the TXNIP/NLRP3 Inflammasome Signal Pathway and Pyroptosis.

Authors:  Xin Liu; Ya-Rong Zhang; Chen Cai; Xian-Qiang Ni; Qing Zhu; Jin-Ling Ren; Yao Chen; Lin-Shuang Zhang; Chang-Ding Xue; Jie Zhao; Yong-Fen Qi; Yan-Rong Yu
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

Review 2.  The immune landscape of esophageal cancer.

Authors:  Tu-Xiong Huang; Li Fu
Journal:  Cancer Commun (Lond)       Date:  2019-11-26

3.  Development of a prognostic signature for esophageal cancer based on nine immune related genes.

Authors:  Zhi Zhang; Cheng Chen; Ying Fang; Sheng Li; Xiaohua Wang; Lei Sun; Guoren Zhou; Jinjun Ye
Journal:  BMC Cancer       Date:  2021-02-04       Impact factor: 4.430

Review 4.  Human Microbiota in Esophageal Adenocarcinoma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Implications.

Authors:  Wanyue Dan; Lihua Peng; Bin Yan; Zhengpeng Li; Fei Pan
Journal:  Front Microbiol       Date:  2022-01-14       Impact factor: 5.640

5.  Development and validation of a prognostic model related to pyroptosis-related genes for esophageal squamous cell carcinoma using bioinformatics analysis.

Authors:  Weiguang Zhang; Peipei Zhang; Junfei Jiang; Kaiming Peng; Zhimin Shen; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2022-08       Impact factor: 3.005

6.  Long non-coding RNA MEG3 mediates the miR-149-3p/FOXP3 axis by reducing p53 ubiquitination to exert a suppressive effect on regulatory T cell differentiation and immune escape in esophageal cancer.

Authors:  Qi-Rong Xu; Jian Tang; Hong-Ying Liao; Ben-Tong Yu; Xiang-Yuan He; Yu-Zhen Zheng; Sheng Liu
Journal:  J Transl Med       Date:  2021-06-17       Impact factor: 5.531

Review 7.  Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma.

Authors:  Qiang Li; Heng Dong; Guangwen Yang; Yuxian Song; Yongbin Mou; Yanhong Ni
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

Review 8.  The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer.

Authors:  Man Wang; Shuai Jiang; Yinfeng Zhang; Peifeng Li; Kun Wang
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639

Review 9.  The Role of Adaptor Protein CARD9 in Colitis-Associated Cancer.

Authors:  Xiaoming Zhong; Bin Chen; Min Liu; Zhiwen Yang
Journal:  Mol Ther Oncolytics       Date:  2019-08-30       Impact factor: 7.200

10.  c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.

Authors:  Lan Zhang; Xiaohui Wang; Yunfei Li; Jing Han; Xianzheng Gao; Shenglei Li; Feng Wang
Journal:  Clin Transl Med       Date:  2021-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.